| Literature DB >> 27540038 |
Apostolos Tzikas1, David R Holmes2, Sameer Gafoor3, Carlos E Ruiz4, Carina Blomström-Lundqvist5, Hans-Christoph Diener6, Riccardo Cappato7,8, Saibal Kar9, Randal J Lee10, Robert A Byrne11, Reda Ibrahim12, Dhanunjaya Lakkireddy13, Osama I Soliman14, Michael Nabauer15, Steffen Schneider16, Johannes Brachmann17, Jeffrey L Saver18, Klaus Tiemann19, Horst Sievert3, A John Camm20, Thorsten Lewalter21.
Abstract
The increasing interest in left atrial appendage occlusion (LAAO) for ischaemic stroke prevention in atrial fibrillation (AF) fuels the need for more clinical data on the safety and effectiveness of this therapy. Besides an assessment of the effectiveness of the therapy in specific patients groups, comparisons with pharmacological stroke prophylaxis, surgical approaches, and other device-based therapies are warranted. This paper documents the consensus reached among clinical experts in relevant disciplines from Europe and North America, European cardiology professional societies, and representatives from the medical device industry regarding definitions for parameters and endpoints to be assessed in clinical studies. Adherence to these definitions is proposed in order to achieve a consistent approach across clinical studies on LAAO among the involved stakeholders and various clinical disciplines and thereby facilitate continued evaluation of therapeutic strategies available. Published on behalf of the European Society of Cardiology. All rights reserved.Entities:
Keywords: Atrial Fibrillation; LAA closure; Prevention; Stroke
Mesh:
Year: 2016 PMID: 27540038 PMCID: PMC5841559 DOI: 10.1093/europace/euw141
Source DB: PubMed Journal: Europace ISSN: 1099-5129 Impact factor: 5.214